Celiac Disease Drug Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2028

The global celiac disease drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Celiac disease is an autoimmune disorder in which a protein called gluten damages the small intestine's membrane. Gluten can be present in grains such as rye, barley, and wheat. Gluten causes an immunological reaction that damages the villi in the small intestine (small finger-like projections in the small intestine which promote absorption). The body's ability to absorb proteins, nutrients, lipids, vitamins, carbs, and minerals is hampered by the damage. This eventually leads to malnutrition. It causes neurological malfunction, infertility, osteoporosis, and anemia if left untreated. Men and women of various ages and races are affected by celiac disease. HLA DQ2 and HLA DQ8 are two of the most critical genes linked to celiac disease. About 30% of the world's population carries one or both genes, however, only one in every 30 people will acquire the condition. Screening and biopsy are used to diagnose the condition. It is estimated that 80% of celiac disease cases go undetected or are misdiagnosed as another disease.

To Request a Sample of our Report on Celiac Disease Drug Market: https://www.omrglobal.com/request-sample/celiac-disease-drug-market

The key players operating in the global celiac disease drug market include Pfizer Inc., Johnson & Johnson Services, Inc., and Bristol-Myers Squibb Co., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease announced the initiation of the Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as 'Non-Responsive Celiac Disease' (NRCD). Moreover, in November 2019, Bristol-Myers Squibb Co., has announced the acquisition of Celgene Corporation, a company that works in celiac disease treatment. This acquisition expands the product portfolio for Bristol company.

Market Coverage

· The market number available for - 2021-2028

· Base year- 2021

· Forecast period- 2022-2028

Segment Covered-

· By Drugs

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Pfizer Inc., Johnson & Johnson Services, Inc., and Bristol-Myers Squibb Co., among others.

(Get 15% Discount on Buying this Report)

A full Report of Celiac Disease Drug Market is Available @ https://www.omrglobal.com/industry-reports/celiac-disease-drug-market

Global Celiac Disease Drug Market Report by Segment

By Drugs

· First Line of Treatment

· Second Line of Treatment

Global Celiac Disease Drug Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.